New Mexico biologics regulations.

Who may administer PRP, exosomes and stem cells in New Mexico, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in New Mexico?

In New Mexico, practitioners administering stem cell therapies must be licensed healthcare providers. Licensed physicians (MDs or DOs) are authorized to conduct biologic treatments, while nurse practitioners or physician assistants may do so under physician supervision.

Official sources

New Mexico compliance guide.

FDA Compliance

The U.S. Food and Drug Administration (FDA) oversees the regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps), including stem cell therapies. Clinics in New Mexico must comply with FDA guidelines for HCT/P, which set standards for minimal manipulation, homologous use, and registration requirements for providers and manufacturers. Ensure that your clinic’s protocols align with these federal guidelines to maintain compliance.

New Mexico State Regulations

In addition to federal standards, clinics must adhere to New Mexico’s Department of Health regulations. While New Mexico does not have specific legislation exclusively for stem cell therapies, it enforces general medical and licensing laws that impact biologics. Understanding these requirements is key to establishing a compliant practice. Regularly review New Mexico health guidelines to stay updated on any emerging standards specific to biologics.

Provider Qualifications

In New Mexico, practitioners administering stem cell therapies must be licensed healthcare providers. Licensed physicians (MDs or DOs) are authorized to conduct biologic treatments, while nurse practitioners or physician assistants may do so under physician supervision. Refer to New Mexico Medical Board’s licensing requirements to ensure your team’s credentials align with state guidelines.

Patient Informed Consent

New Mexico clinics must ensure that patients understand the potential risks and benefits of biologic treatments. Informed consent documentation should outline:

  • Procedure details and expected outcomes.
  • Risks and potential adverse effects.
  • Acknowledgement of the therapy's experimental nature (if applicable).
  • Alternative treatment options.Emphasize transparency in all communications to enhance patient trust and comply with ethical standards.

Additional Compliance Measures

Pre-Treatment and Post-Treatment Protocols

Standardizing protocols for pre- and post-treatment enhances patient safety and regulatory compliance. Develop SOPs that include screening criteria, procedure steps, and follow-up care, documented in compliance with both FDA and state recommendations.

Insurance Requirements

Biologic therapies can pose risks that may impact liability. Clinics should ensure adequate coverage with medical liability insurance specific to biologic or stem cell therapies. Verify that your policy meets state requirements and covers all potential risks associated with these treatments.

Marketing Compliance

New Mexico requires that all clinic advertisements provide accurate and non-misleading information. Avoid unverified claims about the efficacy of stem cell treatments and adhere to FDA advertising guidelines. Clear and honest marketing is essential to maintain both compliance and patient trust.

This guide is a general summary to help clinics understand compliance requirements for biologics in New Mexico. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

New Mexico: common questions.

Who can administer stem cells, PRP and exosomes in New Mexico?
In New Mexico, practitioners administering stem cell therapies must be licensed healthcare providers. Licensed physicians (MDs or DOs) are authorized to conduct biologic treatments, while nurse practitioners or physician assistants may do so under physician supervision. This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in New Mexico?
FDA rules are federal, so they apply in New Mexico as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in New Mexico?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in New Mexico?
Start with the live webinar, then a discovery call and live training. After that we verify your New Mexico licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in New Mexico? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.